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The Impact of Multidrug-Resistant Organisms on 
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Background. Multidrug-resistant organisms (MDROs) are important diabetic foot infection (DFI) pathogens. This study evalu-
ated the impact of DFIs associated with MDRO pathogens (DFI-MDRO) on clinical outcomes.
Methods. Adults admitted to Detroit Medical Center from January 2012 to December 2015 with culture-positive DFI were 
included. Associations between outcomes and DFI-MDRO (evaluated as a single group that included methicillin-resistant 
Staphylococcus aureus [MRSA], vancomycin-resistant enterococci, Enterobacteriaceae resistant to third-generation cephalosporin 
[3GCR-EC], Acinetobacter baumannii, and Pseudomonas aeruginosa) were analyzed. Outcomes included above- and below-knee 
lower extremity amputation (LEA), readmissions, and mortality within a year after DFI. A propensity score predicting the likelihood 
of having DFI-MDRO was computed by comparing patients with DFI-MDRO with patients with DFI with non-MDRO pathogens 
(DFI-non-MDRO). Using conditional logistic regression, DFI-MDRO was analyzed as an independent variable after patients in the 
MDRO and non-MDRO groups were matched by propensity score.
Results. Six hundred forty-eight patients were included, with a mean age ± SD of 58.4 ± 13.7. Most patients in the cohort pre-
sented with chronic infection (75%). DFI-MDRO occurred in greater than one-half of the cohort (n = 364, 56%), and MRSA was 
the most common MDRO (n = 224, 62% of the DFI-MDRO group). In propensity-matched analyses, DFI-MDRO was not asso-
ciated with 1-year LEA or readmissions, but was associated with recurrent DFI episodes (odds ratio, 2.1; 95% confidence interval, 
1.38–3.21).
Conclusions. DFI-MDRO was associated with a 2-fold increased risk of recurrent DFI compared with patients with 
DFI-non-MDRO.
Keywords.  diabetic foot infection; multidrug-resistant organisms.
Among patients with diabetes, 10%–25% will develop diabetic 
foot ulcer (DFU) throughout their lives [1]. Sixty percent of 
DFUs may become infected, leading to a diabetic foot infec-
tion (DFI) [2]. Diabetic foot complications are the leading 
cause of hospitalization among patients with diabetes and are 
associated with an increased risk of lower limb amputation 
[2]. Other consequences of DFI include impaired mobility, 
impaired quality of life, and depression [3, 4]. In addition to 
the associated morbidity, DFI substantially increases health 
care costs, comprising up to 30% of the excess medical costs of 
patients with diabetes [3].
Multidrug-resistant organisms (MDROs) are common 
pathogens in DFI patients [5], due in part to frequent health 
care exposures and repeated courses of antibiotic treatment. 
The growing prevalence of MDROs associated with DFI limits 
antibiotic choices and sometimes leads to suboptimal therapy 
[6–8]. Due to this increased MDRO prevalence and the impor-
tance of early effective antimicrobial therapy, current national 
guidelines recommend the empiric use of broad-spectrum anti-
biotics in patients who have moderate to severe DFI [6].
Although some data suggest that infections due to MDROs 
result in worse outcomes more frequently than susceptible iso-
lates [7, 9, 10], evidence pertaining to the impact of MDROs on 
DFI is conflicting. In several studies, DFI due to MRSA has been 
associated with poor ulcer healing [11], treatment failure [7], 
readmission to the hospital [12], and increased mortality [13], 
and MDROs have been associated with poor glycemic control 
[8]. However, in other studies of DFI, MDROs were not asso-
ciated with worse clinical outcomes [14, 15]. In addition, the 
association between DFIs due to MDROs and lower extremity 
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amputation (LEA) remains unclear. The objective of this study 
was to evaluate the impact of DFI associated with MDROs on 
clinical outcomes, including recurrent DFI, hospital readmis-
sion, and LEA.
METHODS
Study Setting and Cohort Description
The cohort included all adult patients with DFI who were ad-
mitted to the Detroit Medical Center (DMC; a metropolitan 
health system including 4 acute care hospitals and 1 rehabil-
itation center) between January 2012 and December 2015 
with positive cultures from diabetic foot lesions. Potential 
DFI cases were identified based on having an International 
Classification of Diseases, 9th revision (ICD-9), code for dia-
betes mellitus and for skin and soft tissue infection (SSTI) and/
or osteomyelitis (ICD-9 codes that were used were 249, 250, 
680–686, 730). Subsequently admission and discharge notes, 
as well as podiatry and infectious diseases consult notes, were 
reviewed, and actual DFI diagnosis was confirmed by docu-
mented signs and symptoms of infection (erythema, warmth, 
pus drainage, and/or fetid odor). Patients were excluded from 
the study if any of the following were met: (1) infection status 
of the ulcer could not be determined from chart review or in-
fection was ruled out by care providers, (2) the SSTI was not 
related to the foot, (3) infection following a fracture and/or a 
surgical site infection was present, (4) cultures grew organ-
isms that were considered to be contaminants (eg, coagulase-
negative Staphylococcus spp. and/or Corynebacterium spp. 
that grew from only a single set of cultures, or grew only in a 
nonsterile culture) [6, 16]. The institutional review boards of 
Wayne State University and the DMC approved this study for 
waiver of informed consent.
Definitions
The date of DFI diagnosis was defined as the day of the first 
positive culture for a DFI episode. An index episode was de-
fined as the first DFI episode over the study period associated 
with a multidrug-resistant organism (DFI-MDRO), and if a 
subject had no DFI episode with an MDRO during the entire 
study period, then the first DFI episode during the study period 
was considered to be the index episode (DFI-non-MDRO). 
Subjects contributed only 1 unique index episode to the cohort. 
All DFI episodes for all subjects were captured throughout the 
study period both before and after the index episode.
For the purposes of these analyses MDROs included 
methicillin-resistant Staphylococcus aureus (MRSA), 
vancomycin-resistant Enterococcus (VRE), Enterobacteriaceae-
resistant third-generation cephalosporins (3GCR-EC) and/or 
carbapenem, and all antimicrobial susceptibility phenotypes 
of Pseudomonas aeruginosa, Acinetobacter baumannii, and 
Stenotrophomonas maltophilia.
Outcome Definitions
Recurrent DFIs were defined as a DFI episode that occurred 
during the time period spanning from 14 days after the index 
episode until 1 year later. Lower extremity amputation (LEA) 
included below-knee amputation or above-knee amputation 
that occurred during admission for the index episode or within 
1  year of follow-up. In addition, less extensive amputations 
(“other amputations”) were captured during index admission 
and the 1-year follow-up period. Readmission was defined as 
any admission within 1 year of the index episode. Mortality was 
captured within 1 year of an index episode. Length of stay for 
the index admission was calculated from the day of DFI diag-
nosis to the day of discharge.
Study Variables
Data pertaining to demographics, source of admission (home, 
long-term care facilities [LTCFs], transfer from another hos-
pital), hospitalization within the past 90  days, comorbidities 
including the Charlson comorbidity index, insurance type, ad-
mission unit, and severity of sepsis at time of index DFI episode 
diagnosis [17] (determined using the most extreme values of 
the Systemic Inflammatory Response Syndrome Score within 
2  days of DFI diagnosis) were collected. Intensive care unit 
(ICU) admission and mechanical ventilation and acute hemo-
dialysis status were captured within 7 days after the date of the 
DFI diagnosis. Variables associated with diabetes status that 
were collected included highest HbA1C value within 3 months 
before the DFI episode, presence of diabetes-related end-organ 
damage, and ankle-brachial index (ABI) values when available. 
The depth of involvement of DFI was determined based on pro-
viders’ documentation and radiology and pathology findings 
and was classified as superficial, deep tissue, or bone involve-
ment. Definitive therapy was defined as the antimicrobial treat-
ment given following release of microbiology results, including 
susceptibility testing. Duration of antibiotic treatment was cat-
egorized into “inpatient duration of therapy” and “total dura-
tion of therapy.” The latter included inpatient administration as 
well as outpatient treatment, which was determined according 
to discharge notes and prescriptions. Antimicrobial treatment 
information in the 3 months before DFI diagnosis was also ab-
stracted from the medical record.
Surgical interventions were recorded for all DFI episodes, 
including bedside debridement, operating room (OR) de-
bridement, and amputations (including LEA and less extensive 
amputations).
Microbiology
Microbiology data for each patient included cultures obtained 
from DFI lesions and were classified as swab cultures obtained 
at the bedside, tissue cultures obtained at the bedside, swab cul-
tures obtained in the OR, tissue cultures obtained in the OR, 
and bone cultures obtained in the OR. For a given episode, all 
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cultures from the DFI lesion that were obtained within a period 
of 14 days after the index episode date were considered to be 
part of the index DFI episode. A polymicrobial episode was de-
fined as an episode during which more than 1 pathogen was 
recovered.
Data Analysis
Participant characteristics among the cohort and prevalence of 
MDROs were calculated using means and SDs, as well as me-
dians with interquartile range (IQRs) where appropriate.
Baseline characteristics of subjects with DFI-MDRO were 
compared with subjects with DFI-non-MDRO using the Fisher 
exact test. Similarly, subjects with a specific MDRO were com-
pared with subjects without that specific MDRO (eg, subjects 
with DFI associated with P.  aeruginosa [DFI-PA] were com-
pared with subjects without PA [DFI-non-PA]).
A multivariable model predicting DFI-MDRO was developed 
and is described elsewhere [18]. In brief, variables with a P value 
of <.2 in the bivariable analysis were included in a candidate 
logistic regression model. Backwards stepwise regression was 
performed to identify independent predictors for DFI-MDRO. 
Variables predicting DFI-MDRO were then used to compute 
a propensity score [18]. The independent association between 
DFI-MDRO and each outcome was determined by conditional 
logistic regression models with frequency-matching by strata of 
propensity score between DFI-MDRO and DFI-non-MDRO.
Similar analytic methodology was used to identify the impact 
of each individual MDRO on outcomes. For example, a propen-
sity score for having DFI associated with PA (DFI-PA) was com-
puted by comparing subjects with DFI-PA with subjects who 
had DFI without PA (DFI-non-PA), and propensity-matched 
conditional logistic regression was conducted for each outcome.
All P values were 2-sided.
RESULTS
Between 2012 and 2015, 1210 subjects with possible DFI were 
screened. Five hundred sixty-two patients were excluded for 1 
or more of the following reasons: absence of positive cultures, 
skin and soft tissue infection located in an area other than the 
foot, documentation of noninfected diabetic foot ulcer, or iso-
lation of coagulase-negative Staphylococci or Corynobacterium 
spp. from a single nonsterile culture.
Six hundred forty-eight unique subjects were determined to 
have DFI and were included in the study cohort (Table 1). The 
mean age was 58.4 ± 13.7, 64% were male, and 73% were African 
American. The median Charlson comorbidity index (IQR) was 




(n = 284) Crude OR (95% CI)a Adjusted OR (95% CI)
Demography and comorbid conditions
Age, mean ± SD, y 59.2 ± 13.8 57.4 ± 13.6 P = .09
Gender (female), No. (%) 135 (37.1) 96 (33.8) P = .41
Bedridden status, No. (%) 74 (21.1) 36 (13.2) 1.32 (0.81–2.16)
Recent hospitalization, No. (%) 141 (38.7) 56 (19.7) 1.53 (0.99–2.38)
LTCF residence,  
No. (%)
40 (11.0) 18 (6.3) 1.48 (0.74–2.95)
Charlson comorbidity index,  
median (IQR)
5 (3 to 7) 4 (3 to 6) P < .001
CKD, No. (%) 118 (32.4) 65 (22.9) 1.48 (1.00–2.18)
Retinopathy, No. (%) 68 (18.7) 49 (17.3) 1.10 (0.73–1.656)
Neuropathy, No. (%) 308 (84.6) 227 (79.9) 1.38 (0.92–2.07)
PVD, No. (%) 270 (74.2) 172 (60.6) 1.45 (1.00–2.09)
ABI (n = 231), median (IQR) 0.99 (0.69 to 1.20) 0.99 (0.67 to 1.17) P = .36
HbA1C (n = 531), mean ± SD 8.8 ± 2.5 9.4 ± 2.8 P = .01
Management
Inpatient duration of treatment, median (IQR) 9 (6 to 15) 8 (5 to 13) P = .06
Total duration of treatment, median (IQR) 20 (13 to 42) 16 (11 to 34) P = .002
Outcomes (within 1 y)
Recurrent DFI, No. (%) 90 (24.7) 35 (12.3) 2.34 (1.53–3.58) 2.1 (1.38–3.21)
LEA, No. (%) 59 (16.2) 29 (10.2) 1.70 (1.06–2.73) 1.25 (0.74–2.13)
Less extensive amputation, No. (%) 170 (46.7) 145 (51.1) 0.84 (0.62–1.15) 0.79 (0.96–1.35)
Length of stay, median (IQR), d 9 (6 to 13) 7 (5 to 11) P < .001
Readmissions, No. (%) 234 (64.3) 157 (55.3) 1.46 (1.06–2.0) 1.13 (0.80–1.61)
Mortality, No. (%) 23 (7.6) 13 (5.6) 1.38 (0.68–2.78) 0.95 (0.43–2.09)
Abbreviations: ABI, ankle-brachial index; CI, confidence interval; CKD, chronic kidney disease; HbA1C, hemoglobin A1C; LEA, lower extremity amputation; LTCF, long-term care facility; 
MDRO, multidrug-resistant organism; OR, odds ratio; PVD, peripheral vascular disorder. 
aFor continuous variables, P values are presented instead of odds ratios (ie, age, Charlson score, ABI, HbA1C, length of stay, duration of treatment).
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5 (3 to 6), and 83% had peripheral neuropathy. Twenty-five per-
cent of the patients presented with either sepsis or septic shock. 
The majority of patients (63%) had bone involvement with their 
infection.
Three hundred sixty-four patients (56%) had DFI with at least 
1 MDRO (DFI-MDRO). The most common MDRO was MRSA 
(n = 224 patients, 62% of patients who had DFI-MDRO), fol-
lowed by P. aeruginosa (n = 94, 26%), 3GCR-EC (n = 51, 14%), 
and VRE (n  =  52, 14%). Most cultures (n  =  457, 72%) were 
polymicrobial and were obtained in the OR (70%), including 
bone biopsies. One hundred sixty-four subjects had anaerobic 
organisms recovered from their DFI. Ninety patients (13.9%) 
had DFI with more than 1 MDRO, and 20 (3.1%) had DFI with 
3 or more MDROs (18 had 3 MDROs, and 2 had 4 MDROs). 
The most common MDROs recovered from polymicrobial cul-
tures were P. aeruginosa (n = 56) and MRSA (n = 26).
In bivariable analysis, patients who had DFI-MDRO had 
higher prevalence of comorbid conditions were more likely to 
be admitted from long-term care facilities, to be bedridden, 
and to have a history of recent hospitalization compared with 
patients with DFI-non-MDRO (Table 1). In addition, patients 
with DFI-MDRO had a higher frequency of prior use of an an-
tibiotic within the previous 3 months compared with patients 
with DFI-non-MDRO (168, 46.2%, vs 71, 25%; P < .001).
Management
The median duration of inpatient antibiotic treatment (IQR) 
was 9 (6 to 14)  days, and the median duration of total anti-
biotic treatment (IQR) was 18 (12 to 40)  days. Patients with 
DFI-MDRO were treated with longer antibiotic durations than 
patients with DFI-non-MDRO (median of total duration [IQR], 
20 [13 to 42] days and 16 [11 to 34] days, respectively; P = .002). 
Overall, 546 subjects (85%) received treatment that was con-
sidered to be active against all of the pathogens associated with 
DFI, and the median time between the day of DFI diagnosis 
and receiving active therapy (IQR) was 0 (−1 to 1) days. Among 
subjects who had DFI-MDRO, 22% (n  =  79) received defini-
tive therapy that was not active against all pathogens, com-
pared with 8% (n = 23) of DFI-non-MDRO subjects (P < .001). 
Among patients with DFI-VRE, VRE was not treated in 44% of 
cases (n = 23/52); among patients with DFI-PA, P. aeruginosa 
was not treated in 11% of cases (n = 10/94); and among patients 
with DFI-3GCR-EC, the resistant Enterobacteriaceae were not 
treated in 16% of cases (n = 9/51).
Overall, surgical debridement was performed in 89.1% of the 
patients (574), and 323 (49%) had an amputation during their 
admission.
Description of Outcomes in the Cohort
One hundred twenty-five patients (19.3%) had recurrent 
DFI episodes within 1  year of the index episode (Table  1). 
Eighty-eight (14%) underwent lower limb amputation, 391 
(60%) were readmitted, and 36 (7%) patients died within 1 year.
Outcomes Among Patients With DFI-MDRO vs Non-MDRO 
In bivariable analyses, patients with DFI-MDRO were more 
likely to have recurrent DFI (Operating room [OpR], 2.34; 95% 
confidence interval [CI], 1.53–3.58), LEA occurring within 
1 year (OR, 1.7; 95% CI, 1.06–2.7), readmission within 1 year 
(OR, 1.46; 95% CI, 1.06–2.0), and longer duration of hospi-
talization during index admission (median duration [IQR], 9 
[6 to 13] days compared with 7 [5 to 11] days) compared with 
DFI-non-MDRO (P < .001) (Table 1). There was no difference 
in frequency of less extensive amputations or in all-cause mor-
tality between the groups. A propensity score for DFI-MDRO 
included the following predictors for DFI-MDRO: admission 
from an LTCF, prior hospitalization within the last 90  days, 
chronic kidney disease, bedridden status, peripheral vascular 
disease, prior debridement within the last year, use of any 
antibiotic within the last 3  months, and prior diabetic foot 
ulcer with an MDRO. When controlling for differences be-
tween the 2 groups in a propensity-matched model (n = 583) 
(Supplementary Table 1), DFI-MDRO was an independent pre-
dictor for recurrent DFI (OR, 2.02; 95% CI, 1.27–3.22), but not 
for LEA or any other outcomes.
Outcomes Among Patients With DFI-PA 
In bivariate analysis, patients with DFI-PA (as compared with 
patients without DFI-PA) had significantly higher risk for 
higher risk for LEA occurring within 1 year (OR, 2.09; 95% CI, 
1.21–3.62) (Table 2). The duration of hospitalization was longer 
for patients with DFI-PA compared with DFI-non-PA (median 
duration [IQR], 10 [6 to  15] days compared with 8 [5 to  12] 
days; P  =  .009). The propensity score for DFI-PA included 
chronic kidney disease, peripheral vascular disease, admission 
from an LTCF, prior hospitalization within the last 90  days, 
bedridden status, prior diabetic foot ulcer with PA, and prior 
use of cefepime or fluoroquinolones within the past 3 months. 
However, in a propensity score–matched model (n  =  480) 
(Supplementary Table 2), DFI-PA was not associated with any 
of the outcomes.
Outcomes Among Patient With DFI-VRE 
DFI-VRE was associated with a higher prevalence of recurrent 
DFI (OR, 2.19; 95% CI, 1.19–4.06) and LEA within 1 year (OR, 
2.05; 95% CI, 1.03–4.09) (Table  2). The propensity score for 
DFI-VRE included chronic kidney disease, peripheral vascular 
disease, prior diabetic foot ulcer with VRE, prior hospitaliza-
tion within the past 90 days, prior debridement, and prior use of 
vancomycin within the past 3 months. In a propensity-matched 
analysis (n = 437) (Supplementary Table 4), DFI-VRE was as-
sociated with a >2-fold increased risk of having recurrent DFI 
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(OR, 2.57; 95% CI, 1.29–5.12) but was not associated with other 
outcomes.
Outcomes Among Patients With DFI-3GCR-EC 
Patients who had DFI-3GCR-EC had higher risk of LEA 
occurring within 1 year (OR, 3.23; 95% CI, 1.66–6.28) and had 
longer duration of hospitalization (median duration [IQR], 
11 [7 to 18] days) compared with patients who had DFI-non-
3GCR-EC (median duration [IQR], 8 [5 to 12] days; P < .001) 
(Table 2). In addition, the mortality rate was higher in the DFI-
3GCR-EC group (n = 8/51, 19%, vs n = 28/597, 5.7%; OR, 3.9; 
95% CI, 1.65–9.21). The propensity score for DFI-3GCR-EC 
included peripheral vascular disease, congestive heart failure, 
dementia, admission from an LTCF, bedridden status, prior di-
abetic foot ulcer with 3GCR-EC, prior hospitalization within 
the past 90 days, prior use of third-generation cephalosporin, 
and receipt of cefepime or a beta-lactam/beta-lactamase inhib-
itor within the past 3 months. In propensity-matched analyses 
(n = 438) (Supplementary Table 3), DFI-3GCR-EC was associ-
ated with recurrent DFI within 1 year (OR, 2.12; 95% CI, 1.00–
4.51), but not with other outcomes.
Outcomes Among Patients With DFI-MRSA 
In bivariable analysis, patients with DFI-MRSA were at higher 
risk for recurrent DFI within 1  year compared with patients 
with DFI-non-MRSA (OR, 1.52; 95% CI, 1.02–2.26) (Table 2). 
The propensity score for DFI-MRSA included diabetic neurop-
athy, dementia, bedridden status, prior diabetic foot ulcer with 
MRSA, prior debridement, and prior use of beta-lactam within 
the past 3 months.
In a propensity-matched model (n  =  452) (Supplementary 
Table 5), there was no association between DFI-MRSA and any 
of the outcomes. However, there was a trend toward signifi-
cantly higher likelihood of having recurrent DFI within 1 year 
(OR, 1.47; 95% CI, 0.99–2.18).
DISCUSSION
In this cohort of poorly controlled diabetic patients with DFI 
and a high degree of comorbidity, almost 60% of the patients 
had infection involving at least 1 MDR pathogen, and in one-
quarter of DFI-MDRO cases, more than 1 MDRO was recovered. 
MRSA was the most common MDRO recovered, followed 
by P.  aeruginosa, VRE, and third-generation cephalosporin-
resistant Enterobacteriaceae.
Patients who had DFI involving MDRO pathogens had a 
>2-fold increased risk for having recurrent DFI and a prolonged 
duration of hospitalization during their index admission, com-
pared with patients who had DFI involving only susceptible 
pathogens. Similar associations were observed for each indi-
vidual type of MDRO. Interestingly, although other outcomes, 
such as LEA, readmission, and mortality, were more preva-
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who had DFI-non-MDRO, none of these outcomes was inde-
pendently associated with DFI-MDRO in propensity-adjusted 
analyses. Other studies have reported weak or no association 
between MDRO and DFI outcomes [14, 19]. To our knowledge, 
this is the largest study that has evaluated the impact of indi-
vidual MDROs on LEA.
Several reasons may have explain the lack of an independent 
association between MDRO and certain outcomes including 
LEA, readmission, and mortality. First, the majority of the pa-
tients in both the DFI-MDRO and DFI-non-MDRO groups 
had polymicrobial infections, with various combinations of 
different types of pathogens. Nevertheless, in both of the study 
groups, the majority of patients received therapy with in vitro 
activity against all pathogens present (effective therapy) during 
the index episode. Given that both groups received effective 
therapy, any expected differences in DFI outcomes related to the 
presence of MDROs may have been obviated. In instances where 
therapy did not provide activity against all MDROs present, the 
most common MDRO not treated was VRE. The role of VRE 
as a true pathogen, particularly in the setting of polymicrobial 
infection, is debatable [20]. Second, most of the patients who 
were treated for DFI had chronic infection (only 25% of patients 
in the cohort presented with signs and symptoms of sepsis or 
septic shock). In the setting of chronic infection, factors such 
as peripheral neuropathy and poor vascular supply may have a 
greater impact on ulcer healing than the presence of MDROs. 
Finally, surgical debridement and source control are critical 
components of the effective management of DFI, and these as-
sociations are likely independent of MDRO status.
The frequency of MDROs in this cohort from metro Detroit 
was extremely high (approaching 60%). This high frequency of 
MDRO pathogens raises the question of whether, in some set-
tings, empiric antibiotic regimens for DFI should include cov-
erage for MDROs. Although MDROs were not independently 
associated with some adverse outcomes including readmission, 
LEA, and mortality, they were associated with recurrent DFI and 
increased duration of hospitalization. Prospective controlled 
studies are needed to better understand the role of broad-spec-
trum empiric antibiotic therapy that provides coverage against 
MDROs in the management and clinical outcomes of patients 
with DFI-MDRO.
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